DotBio: Funding, Investors & Team (Oct 2026)
DotBio uses its exclusive DotBody technology to create multi-functional antibodies, which are the future of cancer treatment. These antibodies target various interactions between tumors and the tumor microenvironment in order to restore a strong immune response. Our unique technologies allow for the quick development of multi-specific antibodies that can target multiple processes. By testing combinations of these antibodies, we can quickly identify molecules that reactivate the immune response against tumors using innovative synergistic mechanisms.
DotBio has raised $5.6M across 1 funding round on record, the most recent a Seed of $5.6M announced in Aug 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
DotBio Company Profile and Key Stats
Latest funding round on record: Aug 2023.
DotBio Funding Rounds
DotBio Founders and Leadership Team
No contact details are on record for this team yet.
DotBio Funding Compared to Other Biotechnology Startups
DotBio's latest round of $5.6M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like DotBio in Biotechnology and Singapore
Companies Similar to DotBio
YouLabs is an early-stage, data-driven biotechnology and longevity technology company focused on shifting…
Volition is a worldwide life sciences organization creating straightforward, simple to utilize blood-based…
ImmunoScape is a company focused on immunomics, using a technology platform to analyze and characterize the…
Nuevocor, which has locations in both the United States and Singapore, is working on creating genetic…
Aevice Health Pte Ltd is a Singaporean company that originated from Nanyang Technological University and…
Mirxes is a biotech firm focused on uncovering, advancing, and providing precise preventive healthcare…
BioDefense introduces Bioshield, a product derived from edible ingredients designed to safeguard your food by…
Auristone delivers practical clinical insights through our epigenomics workflows, providing actionable…
ASLAN is a pharmaceutical company that develops novel medicines for global markets. It specializes in…
GDMC is a pharmaceutical organization that specializes in the production and development of genetic…
Meatiply, a company focused on food research, specializes in the creation and manufacturing of meat…
Empowering Healthier Meals by Harnessing the Best from Nature and Combining that our Knowledge of Food…
DotBio Funding FAQs
What does DotBio do?
DotBio uses its exclusive DotBody technology to create multi-functional antibodies, which are the future of cancer treatment. These antibodies target various interactions between tumors and the tumor microenvironment in order to restore a strong immune response. Our unique technologies allow for the quick development of multi-specific antibodies that can target multiple processes. By testing combinations of these antibodies, we can quickly identify molecules that reactivate the immune response against tumors using innovative synergistic mechanisms.
How much funding has DotBio raised?
DotBio has raised $5.6M across 1 round on record. The most recent is a Seed of $5.6M announced in Aug 2023.
When did DotBio last raise funding?
DotBio's most recent funding round on record is a Seed of $5.6M, announced in Aug 2023.
Who is the CEO of DotBio?
Ignacio Nacho Asial is listed as CEO at DotBio.
Where is DotBio headquartered?
DotBio is based in Singapore, Central Region, Singapore.
How many employees does DotBio have?
DotBio is in the 11-50 employee band.
How does DotBio's funding compare to other Biotechnology startups?
DotBio's latest round of $5.6M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's DotBio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for DotBio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.